medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-8-46-51medsovet-2432Research ArticleПрактикаPracticeПероральные цефалоспорины в практике лор-врачаOral cephalosporins in the ent-practiceМорозоваС. В.MorozovaS. V.

д.м.н., профессор

MD, Prof.

СвистушкинМ. В.SvistushkinM. V.Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation201819042018084651Copyright © Морозова С.В., Свистушкин М.В., 20182018Морозова С.В., Свистушкин М.В.Morozova S.V., Svistushkin M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2432

В статье представлены современные данные об адекватной антибактериальной терапии острых инфекционно-воспалительных заболеваний верхних отделов дыхательных путей и уха, приводится краткий обзор наиболее часто применяемых антибиотиков в практике врача-оториноларинголога, а также клинические исследования, посвященные изучению эффективности и безопасности препарата Спектрацеф, активным веществом которого является цефдиторен – представитель группы цефалоспоринов.

 

The article presents modern data on antibacterial therapy for acute infectious and inflammatory diseases of the upper respiratory tract and ear, provides a overview of the most commonly used antibiotics in the practice of ENT, as well as clinical studies devoted to the study of the efficacy and safety of the drug Spectracef – a representative of the cephalosporin group.

 

острый тонзиллофарингитострый бактериальный риносинуситострый средний отитантибиотикотерапияцефалоспориныцефдиторенСпектрацефacute tonsillopharyngitisacute bacterial rhinosinusitisacute otitis mediaantibiotic therapycephalosporinscefditorenSpectracefReferencesAin MR, Shahzad N, Aqil M, Alam MS, Khanam R. Drug utilization pattern of antibacterials used in ear, nose and throat outpatient and inpatient departments of a university hospital at New Delhi, India. Journal of Pharmacy and Bioallied Sciences, 2010, 2(1): 8-12. doi: 10.4103/0975-7406.62695.Ain MR, Shahzad N, Aqil M, Alam MS, Khanam R. Drug utilization pattern of antibacterials used in ear, nose and throat outpatient and inpatient departments of a university hospital at New Delhi, India. Journal of Pharmacy and Bioallied Sciences, 2010, 2(1): 8-12. doi: 10.4103/0975-7406.62695.Buchineni, Madhavulu & Pathapati, Rama & Srinivas, Golve & Kudagi, Babasaheb. (). Drug utilization study of antimicrobials in ent out patient department in a tertiary care hospital in south india. Asian academic research journal of multidisciplinary, 2014, 1: 426-432.Buchineni, Madhavulu & Pathapati, Rama & Srinivas, Golve & Kudagi, Babasaheb. (). Drug utilization study of antimicrobials in ent out patient department in a tertiary care hospital in south india. Asian academic research journal of multidisciplinary, 2014, 1: 426-432.Kishore Kumar Y, Cheekavolu C, Obulesu G. Drug utilization pattern in ENT OPD of government tertiary care teaching hospital in Raigarh. International Journal of Otorhinolaryngology and Head and Neck Surgery, 2017 sep, 3(4): 1042-1045.Kishore Kumar Y, Cheekavolu C, Obulesu G. Drug utilization pattern in ENT OPD of government tertiary care teaching hospital in Raigarh. International Journal of Otorhinolaryngology and Head and Neck Surgery, 2017 sep, 3(4): 1042-1045.Vanitha M. Prescribing Pattern of Antibiotics in Patients Attending ENT OPD in A Tertiary Care Hospital. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 2017, 16.9: 30-33. doi: 10.9790/0853-1609023033.Vanitha M. Prescribing Pattern of Antibiotics in Patients Attending ENT OPD in A Tertiary Care Hospital. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 2017, 16.9: 30-33. doi: 10.9790/0853-1609023033.Sathiya Sanket B. et al. Drug utilization pattern of antimicrobial agents in an outpatient department of otorhinolaryngology in a tertiary care hospital: a prospective, cross-sectional study. International Journal of Basic & Clinical Pharmacology, 2016 dec, 5(1): 65-69. doi. org/10.18203/2319-2003.ijbcp20160102Sathiya Sanket B. et al. Drug utilization pattern of antimicrobial agents in an outpatient department of otorhinolaryngology in a tertiary care hospital: a prospective, cross-sectional study. International Journal of Basic & Clinical Pharmacology, 2016 dec, 5(1): 65-69. doi. org/10.18203/2319-2003.ijbcp20160102Kousalya K, Thirumurugu S, Arumainayagam DC, Manavalan R, Vasantha J, Reddy CUM. Antimicrobial resistance of bacterial agents of the upper respiratory tract in south indian population. Journal of Advanced Pharmaceutical Technology & Research, 2010, 1(2): 207-215.Kousalya K, Thirumurugu S, Arumainayagam DC, Manavalan R, Vasantha J, Reddy CUM. Antimicrobial resistance of bacterial agents of the upper respiratory tract in south indian population. Journal of Advanced Pharmaceutical Technology & Research, 2010, 1(2): 207-215.Wang L, Qiao X, Ai L, Zhai J, Wang X. Isolation of antimicrobial resistant bacteria in upper respiratory tract infections of patients. 3 Biotech, 2016, 6(2): 166. doi: 10.1007/s13205-016-0473-z.Wang L, Qiao X, Ai L, Zhai J, Wang X. Isolation of antimicrobial resistant bacteria in upper respiratory tract infections of patients. 3 Biotech, 2016, 6(2): 166. doi: 10.1007/s13205-016-0473-z.Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety, 2014, 5(6): 229-241. doi: 10.1177/2042098614554919.Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety, 2014, 5(6): 229-241. doi: 10.1177/2042098614554919.Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiology spectrum, 2016, 4(2). doi: 10.1128/microbiolspec.VMBF-0016-2015.Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiology spectrum, 2016, 4(2). doi: 10.1128/microbiolspec.VMBF-0016-2015.Von Wintersdorff CJH, Penders J, van Niekerk JM, et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. Frontiers in Micro biology, 2016, 7: 173. doi: 10.3389/fmicb.2016.00173.Von Wintersdorff CJH, Penders J, van Niekerk JM, et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. Frontiers in Micro biology, 2016, 7: 173. doi: 10.3389/fmicb.2016.00173.Белоцерковский Б.З., Гельфанд Е.Б. и соавт. Место и эффективность цефоперазона/сульбактама в хирургии и интенсивной терапии (краткий обзор литературы и собственные наблюдения). Consilium medicum. Инфекции в хирургии, 2007, 5(2): 43-51.Belocerkovsky B.Z., Gelfand E.B. et al. The place and efficacy of cefoperazone/sulbactam in surgery and intensive care (a brief review of the literature and own observations). Consilium Medicum. Surgery infection, 2007, 5(2): 43-51.García-Rodríguez JA, Muñoz Bellido JL, García Sánchez JE. Oral cephalosporins: current perspectives. International Journal of Antimicrobial Agents, 1995, 5(Issue 4): 231-243. https: //doi. org/10.1016/0924-8579(95)00015-Z.García-Rodríguez JA, Muñoz Bellido JL, García Sánchez JE. Oral cephalosporins: current perspectives. International Journal of Antimicrobial Agents, 1995, 5(Issue 4): 231-243. https: //doi. org/10.1016/0924-8579(95)00015-Z.Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus infuenzae, Moraxella catarrhalis and Streptococcus-pneumoniae in the United States. Antimicrob Agents Chemother, 1990, 34: 2075-2080.Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus infuenzae, Moraxella catarrhalis and Streptococcus-pneumoniae in the United States. Antimicrob Agents Chemother, 1990, 34: 2075-2080.Lark RL & Chenoweth C. Antimicrobial resistance in community-acquired respiratory tract pathogens. Comprehensive Therapy, 1999, 25(1): 20. https: //doi.org/10.1007/BF02889831.Lark RL & Chenoweth C. Antimicrobial resistance in community-acquired respiratory tract pathogens. Comprehensive Therapy, 1999, 25(1): 20. https: //doi.org/10.1007/BF02889831.Coffey TJ, Dowson CG, Daniels M, Spratt BG. Genetics and molecular biology of β-lactamresis tant pneumococci. Microb. Drug. Resist, 1995, 1: 29–34.Coffey TJ, Dowson CG, Daniels M, Spratt BG. Genetics and molecular biology of β-lactamresis tant pneumococci. Microb. Drug. Resist, 1995, 1: 29–34.Williams JD. Classification of cephalosporins. Drugs, 1987, 34(suppl 2): 15-22.Williams JD. Classification of cephalosporins. Drugs, 1987, 34(suppl 2): 15-22.Thornsberry C. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis, 1992, 14: 189-194.Thornsberry C. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis, 1992, 14: 189-194.Doern G. In vitro activity of loracarbef, and effects of susceptibility test methods. Am J Med, 1992, 92(suppl 6A): 7-15.Doern G. In vitro activity of loracarbef, and effects of susceptibility test methods. Am J Med, 1992, 92(suppl 6A): 7-15.Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixi-me, cefdinir, cefetamet, ceftibuten, oracarbef, cefprozil, BAY 3522.Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixi-me, cefdinir, cefetamet, ceftibuten, oracarbef, cefprozil, BAY 3522.Козлов Р.С., Дехнич А.В. Цефдиторен пивоксил: клинико-фармакологическая и микробиологическая характеристика. Клин. микробиол. анти-микроб. химиотер., 2014, 16(2): 111-129Kozlov R.S., Dechnich A.V. Cefditoren of pivoxil: clinical, pharmacological and microbiological characteristics. CMAC, 2014, 16(2): 111-129.Дифференциальная диагностика и лечение острого тонзиллофарингита. Клинические рекомендации. Национальная медицинская ассоциация оториноларингологов, 2016: 12-14.Differential diagnosis and treatment of acute tonsillopharyngitis. Clinical recommendations. National medical Association of otolaryngologists, 2016: 12-14.Принципы этиопатогенетической терапии острых синуситов. Клинические рекомендации. Национальная медицинская ассоциация оториноларингологов, 2016: 14-17.Principles of etiopathogenetic therapy of acute sinusitis. Clinical recommendations. National medical Association of otolaryngologists. 2016: 14-17.Yamada M, Watanabe T, Miyara T et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother, 2007, 51: 45-50.Yamada M, Watanabe T, Miyara T et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother, 2007, 51: 45-50.Asahi Y, Takeuchi Y, and Ubukata K.. Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother, 1999, 43: 1252–1255.Asahi Y, Takeuchi Y, and Ubukata K.. Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother, 1999, 43: 1252–1255.Purdue Pharmaceutical Products L.P. Package insert: Spectracef® tablets (cefditoren pivoxil) [online]. Available from URL: http: //www.pharma.com/PI/ Prescription/spectracef.pdf Accessed 2004 Aug 23.Purdue Pharmaceutical Products L.P. Package insert: Spectracef® tablets (cefditoren pivoxil) [online]. Available from URL: http: //www.pharma.com/PI/ Prescription/spectracef.pdf Accessed 2004 Aug 23.Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren [poster no. 310]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 Sep 17-20, Toronto.Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren [poster no. 310]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 Sep 17-20, Toronto.FDA Spetracef Patient Information Leaflet dated 08.06.2012.FDA Spetracef Patient Information Leaflet dated 08.06.2012.Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter, 2009, 22: 57-61.Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter, 2009, 22: 57-61.Реестр лекарственных средства – www.rls.net. Ссылка активна на 23.02.18.Drugs reestr. www.rls.net. Accessed at 23.02.18Свистушкин В.М., Славский А.Н., Пшонкина Д.М. Бактериофаги в комплексном лечении острого бактериального риносинусита, РМЖ, 2014, 26: 19-25.Svistushkin V.M., Slavsky A.N., Pshonkina D.M. Bacteriophages in complex treatment of acute bacterial rhinosinusitis. RMJ, 2014, 26: 19-25.

The authors declare that there are no conflicts of interest present.